- Ivarmacitinib, a JAK1 inhibitor, improved symptoms in moderate to severe eczema.
- 42% of 8 mg group, and 36.3% of 4 mg group achieved clear or nearly clear skin.
- Reduction in EASI-75 and itch were observed.
- Symptom relief was observed early in the trial. 5. Adverse events included upper respiratory infections and mild laboratory changes.
Source: JAMA Dermatology
